{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-22-000052","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2022-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.536108+00:00","generated_at":"2026-06-23T10:50:45.198497+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AnaptysBio sells Zejula royalty rights to DRI Healthcare for $35M upfront","bullets":["Received $35M upfront from DRI for all future Zejula royalties from GSK (effective July 2022).","Eligible for additional $10M milestone if Zejula approved for endometrial cancer by Dec 31, 2025.","Current effective royalty rate is 0.5% of global Zejula net sales.","Agreement includes customary covenants; Purchase Agreement to be filed in Q3 2022 10-Q."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-22-000052","json":"https://secwatch.observer/filing/0001370053-22-000052.json","markdown":"https://secwatch.observer/filing/0001370053-22-000052.md","text":"https://secwatch.observer/filing/0001370053-22-000052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005322000052/0001370053-22-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005322000052/anab-20220909.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T10:50:45.198497+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}